2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
154
Sarcoma
20
Tumor-Agnostic
11
Genitourinary
11
Gynecologic
8
Thoracic
7
Other solid neoplasm
6
CNS
5
Gastrointestinal
4
Lymphoid
2
Head & Neck
2
Dermatologic
2
Conditions
Neoplasms
2
Lymphoma
2
Interventions
Rituximab
1401
Cyclophosphamide
1306
Vincristine
668
Doxorubicin
587
Etoposide
527
Prednisone
511
Cytarabine
486
fludarabine
470
Methotrexate
445
Dexamethasone
413
fludarabine phosphate
400
Lenalidomide
356
Filgrastim
343
Bendamustine Hydrochloride
282
Radiotherapy
267
venetoclax
261
ibrutinib
258
obinutuzumab
236
Peripheral Blood Stem Cell Transplantation
234
Melphalan
230
Granulocyte Colony-Stimulating Factor
215
Bortezomib
204
Gemcitabine
202
Busulfan
188
Whole-Body Irradiation
187
Mycophenolic Acid
175
Tacrolimus
165
Specimen Handling
162
Magnetic Resonance Spectroscopy
155
Calcium Dobesilate
150
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
eribulin
×
Lymphoid
×
Clear all
NCT02082626
2020-03-10
ERIBULIN
University of Oklahoma
Phase 1
Terminated
3 enrolled
NCT02171260
2019-01-15
BOLD 113
Eisai Inc.
Phase 1
Completed
23 enrolled
22 charts